Continuity Image Blogs
Read article Continuity Without Compromise: How KCAS Bio Delivers End‑to‑End Bioanalytical Support Across Modalities

In today’s fast-moving drug development landscape, bioanalytical continuity and end-to-end support aren’t just conveniences, they’re competitive advantages. Sponsors navigating complex modalities like gene therapies, ADCs, oligonucleotides, and biologics need a partner who can keep pace with aggressive timelines, shifting priorities, and evolving regulatory expectations. Why Continuity Matters in Bioanalysis…

Two Protein Biomarkers Hybrid LC-MSMS_KCAS Bio 1 Posters & Papers
Read article Method Development and Validation for the Determination of Two Protein Biomarkers by Multiplexed Online and Offline Hybrid LC-MS/MS in Human Heart Tissue

Discover in this poster presented by Taylor Dufield at WRIB 2026 on how a fit-for-purpose multiplex LC–MS/MS workflow combining online and offline anti-peptide immunoprecipitation that enables sensitive, selective quantitation of protein biomarkers and binding partners from a single digested tissue sample across multiple species using a validated ICH M10-aligned approach.

Biomarker Analog by Hybrid LC-MSMS_KCAS Bio Posters & Papers
Read article Method Development and Validation of a Biomarker Analog by Hybrid LC-MS/MS with Two-Dimensional Chromatography in Human Matrices

Discover in this poster presented by Ryan Darling at WRIB 2026 on how a validated hybrid immunoaffinity LC–MS/MS method using a surrogate peptide and 2D chromatography enables selective, sub-ng/mL quantitation of a KLK1 analog in human plasma, overcoming LBA limitations caused by near-identical endogenous KLK1. If you have any questions…

ADC_ARC Conjugates Presentation AAPS 2025_KCAS Bio Posters & Papers
Read article Bioanalytical Strategies for Therapeutic Drugs and Their Conjugates (ADCs, Oligos, siRNA, ASOs and AOCs/ARCs) by QqQ/HRMS – Strategies and Case Studies

This presentation, given at the 2025 AAPS PharmSci Conference by Dawn Dufield, PhD, Scientific Officer of Mass Spectrometry at KCAS Bio, reviews Bioanalytical Strategies for Therapeutic Drugs and Their Conjugates (ADCs, Oligos, siRNA, ASOs and AOCs/ARCs) by QqQ/HRMS. If you have any questions about these services or any others offered…

UNDERSTANDING HYBRID LC-MS/MS BIOANALYSIS Blogs
Read article Understanding Hybrid LC-MS/MS Bioanalysis

Hybrid LC-MS/MS is a technique that combines an affinity capture step with LC-MS/MS detection. It typically requires only one antibody, in contrast to conventional ligand-binding assays (LBAs), which usually need two. This approach leverages the combined selectivity of affinity extraction and the analytical power of tandem mass…

Method Development and Validation of a Biomarker Analog by Hybrid LC-MS/MS with Two-Dimensional Chromatography in Human Matrices Posters & Papers
Read article Development of a High Throughput LC-MS/MS 1.5 Plex Assay for Quantitation of Total Antibody (TAb) and Intact Antibody Drug Conjugate (ADC) using Immunoprecipitation by Specific Receptor Capture

Discover in this poster presented by Ryan Darling at the AAPS National Biotechnology Conference 2025 on the use of a hybrid LC-MS/MS approach for the quantitation of total antibody TAb and intact Antibody Drug Conjugate (ADC). If you have any questions about these services or any others offered…

ADC ANALYSIS – FREQUENTLY ASKED QUESTIONS BLOG Blogs
Read article ADC Analysis – Frequently Asked Questions

ADCs represent a promising class of targeted therapies, and understanding the intricacies of their analysis is crucial for their successful development. In this blog, we address common questions to guide you through the various considerations involved in ADC research and testing. We will cover key topics related to the…

KCAS-blog-thumb_2025_ADC1 Blogs
Read article Maximizing Efficiencies of ADC Studies: The Ultimate Guide for Leveraging LBA and LC-MS/MS Under One Roof

Antibody-drug conjugates (ADCs) have been conventionally developed for a wide range of oncological applications since the first ADC approval in 2000 by the FDA. Typically, an ADC consists of three main components: antibody, linker conjugate, and therapeutic drug (payload). The mechanism of an ADC involves the antibody binding to a specific…

KCAS-webinar-thumb_2024-09_Hybrid LC-MS_MS webinars
Read article Hybrid LC-MS/MS Technology Becoming the New Norm in the Bioanalysis of Antibody-Drug Conjugates

As the pharmaceutical industry continues to evolve, so does the technology behind drug development. One of the most groundbreaking advancements in bioanalysis is Hybrid LC-MS/MS technology, which is rapidly becoming the new standard for analyzing Antibody Drug Conjugates (ADCs). KCAS Bio is proud to be at the forefront of this…

KCAS-blog-thumb_2024-05_Novel PK Bioanalytical Approach Blogs
Read article Hybrid LC-MS/MS PK Assay for ADC and ARC Quantification

The age of therapeutic conjugation is upon us! Bioanalysis for support of next-generation Antibody Drug Conjugates (ADCs) and Antibody siRNA Conjugates (ARCs) have exploded recently due to the efficacy and safety that these therapies offer for immuno-oncology, rare diseases, vaccines, and potentially many other diseases. Recently, we have seen the…

kcas-poster-presentation_wrib-2024 Blogs
Read article KCAS Bio Presents Automated ISR Selection at WRIB 2024

Those of you attending the 18th annual WRIB meeting in San Antonio, TX are invited to attend a poster presentation being given by members of the KCAS Bio team: Jack Rogers, Jessie Allen, Yoka Thomas, and Cheikh Kane. This project developed and characterized a novel algorithm for automated ISR selection…

KCAS-blog-thumb_2024-04-DawnDufield (1) Blogs
Read article Dawn Dufield to Present at WRIB 2024

Dawn Dufield, PhD is the Scientific Officer for Mass Spectrometry and has been with KCAS Bio since 2018. Before joining KCAS Bio, she worked in the quantitative large and small molecule LC-MS/MS field for Pfizer for over 20 years. Dawn has been a pioneer in the Hybrid LCMS field and…